<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516408</url>
  </required_header>
  <id_info>
    <org_study_id>Vtrial</org_study_id>
    <nct_id>NCT04516408</nct_id>
  </id_info>
  <brief_title>Recombinant Zoster Vaccine in Stable SLE Patients</brief_title>
  <official_title>Efficacy and Safety of Recombinant Zoster Vaccine in Stable SLE Patients(Vtrial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of herpers zoster reactivation is higher in SLE patients than general population. It&#xD;
      has shown that mild or even inactive patients could also have varicella zoster virus (VZV)&#xD;
      infections, and they account for about two-thirds of the events. And our previous study&#xD;
      indicated that recent various VZV infection was associated with increased risk of disease&#xD;
      flares. The risk of virus reactivation limited the use of live-attenuated shingles vaccine in&#xD;
      SLE patients, especially in whom with high dose of prednisone or immunosuppressants. Whether&#xD;
      the introduction of recombinant zoster vaccine could reduce the risk of zoster reactivation&#xD;
      in lupus patients is to be explored in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that requires&#xD;
      long-term corticosteroid and/or immunosuppressive agents. Thus lupus patients are&#xD;
      immunocompromised patients, and the incidence of herpes zoster is higher than general&#xD;
      population (asian population 32.5-91.4/1000 person-years vs general population 2.58-4.89/1000&#xD;
      person-years). Patients with active SLE are more susceptible because they require stronger&#xD;
      immunosuppressive therapy. However, even mild or even stable lupus patients are highly&#xD;
      susceptible, and they account for about two-thirds of the events. In addition, herpes zoster&#xD;
      may trigger lupus flare. A case-control study showed a close correlation between herpes&#xD;
      zoster reactivation and the diagnosis of lupus, and our previous studies indicated that&#xD;
      recent VZV infection was associated with increased risk of disease flares. The risk of virus&#xD;
      reactivation limited the use of live-attenuated shingles vaccine in SLE patients, especially&#xD;
      in whom with high dose of prednisone or immunosuppressants. Whether the introduction of&#xD;
      recombinant herpes zoster could reduce the risk of zoster reactivation in lupus patients is&#xD;
      to be explored in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Herpes Zoster</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of participants with herpes zoster</measure>
    <time_frame>12 months</time_frame>
    <description>The efficacy of recombinant zoster vaccine in stable systemic lupus patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline, 3 month, and 12 month</time_frame>
    <description>Humoral immunity was measured as geometric mean concentrations (GMCs) of serum anti-gE antibodies (ELISA), and CMI was measured as the frequency of CD4 T cells expressing ≥ 2 of 4 selected activation markers (interferon-γ, interleukin-2, tumour necrosis factor-α and CD40 ligand) per 10^6 CD4 T cells after stimulation with gE peptides (hereafter referred to as CD4^2+ T cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants with lupus flares</measure>
    <time_frame>12 months</time_frame>
    <description>either minor/moderate flare or major flare defined by SLEDAI Flare Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of interferon score during follow-up</measure>
    <time_frame>12 months</time_frame>
    <description>Interferon score is detected at each visit, the time of herpes zoster and lupus flare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate for adverse effects following immunization patients will submit the adverse effects by app tracking system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Recombinant Zoster Vaccine</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Recombinant zoster vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the vaccine 2 months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients were randomized in a 1:1 ratio to recombinant zoster vaccine/placebo on the background of standard of care (SOC). Participants received two intramuscular doses of the placebo (sterilized water) 2 months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant zoster vaccine</intervention_name>
    <description>Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.</description>
    <arm_group_label>Recombinant zoster vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterilized water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 50 years old&#xD;
&#xD;
          2. The disease status is stable (score≤ 6 at screening on SELENA-SLEDAI); no British&#xD;
             Isles Lupus Assessment Group (BILAG) A and no more than one BILAG B;&#xD;
&#xD;
          3. A stable treatment regimen with fixed doses of prednisone (≤ 20mg/day), antimalarial,&#xD;
             or immunosuppressive drugs (azathioprine/mycophenolate mofetil/&#xD;
             methotrexate/ciclosporin/tacrolimus/leflunomide/belimumab);&#xD;
&#xD;
          4. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &gt; 2 times upper normal&#xD;
             limits; creatinine clearance rate &lt; 60ml/min;&#xD;
&#xD;
          2. Exposure to cyclophosphamide within the past half year.&#xD;
&#xD;
          3. Exposure to rituximab within the past one year.&#xD;
&#xD;
          4. History of herpes zoster within the past three months;&#xD;
&#xD;
          5. Pregnancy or lactation;&#xD;
&#xD;
          6. History of malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fangfang Sun, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital, Shouth Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fangfang Sun, MD.</last_name>
    <phone>86 15800901145</phone>
    <email>Fiona_rj@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shuang Ye, MD</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Ye, MD</last_name>
      <phone>+8613817615871</phone>
      <email>ye_shuang2000@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Huijing Wang, postgraduate</last_name>
      <phone>+8618267851823</phone>
      <email>whj30813@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

